EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR-T State of the Art and Future Challenges, A Regulatory Perspective

Lorenzo Giorgioni iD, Alessandra Ambrosone, Maria Francesca Cometa, Anna Laura Salvati, Armando Magrelli iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241411803 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lorenzo Giorgioni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Physiology and Pharmacology "V. Erspamer", Sapienza Università di Roma, 00185 Rome, Italy. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review is an outlook on CAR-T development up to the beginning of 2023, with a special focus on the European landscape and its regulatory field, highlighting the main features and limitations affecting this innovative therapy in cancer treatment. We analysed the current state of the art in the EU and set out a showcase of the field’s potential advancements in the coming years. For this analysis, the data used came from the available scientific literature as well as from the European Medicines Agency and from clinical trial databases. The latter were investigated to query the studies on CAR-Ts that are active and/or relevant to the review process. As of this writing, CAR-Ts have started to move past the “ceiling” of third-line treatment with positive results in comparison trials with the Standard of Care (SoC). One such example is the trial Zuma-7 (NCT03391466), which resulted in approval of CAR-T products (Yescarta™) for second-line treatment, a crucial achievement for the field which can increase the use of this type of therapy. Despite exciting results in clinical trials, limitations are still many: they regard access, production, duration of response, resistance, safety, overall efficacy, and cost mitigation strategies. Nonetheless, CAR-T constructs are becoming more diverse, and the technology is starting to produce some remarkable results in treating diseases other than cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptors, Chimeric AntigenHumansImmunotherapy, AdoptiveTechnologyClinical Trials as Topic

Stichwörter der Autor:innen

ATMPCAR-TEMAcompassionate usehospital exemptionrare diseases

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Faculty of Physiology and Pharmacology "V. Erspamer", Sapienza Università di Roma, 00185 Rome, Italy.
  • Faculty of Medicine and Pharmacy, Sapienza Università di Roma, 00185 Rome, Italy.
  • National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy.
  • Faculty of Pharmacy, Tor Vergata University of Rome, 00133 Rome, Italy.

ORCID-Profile: Lorenzo Giorgioni, Armando Magrelli

Zitieren

APA

Giorgioni, L., Ambrosone, A., Cometa, M. F., Salvati, A. L., & Magrelli, A. (2023). CAR-T State of the Art and Future Challenges, A Regulatory Perspective. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411803

Vancouver

Giorgioni L, Ambrosone A, Cometa MF, Salvati AL, Magrelli A. CAR-T State of the Art and Future Challenges, A Regulatory Perspective. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411803

BibTeX
@article{Giorgioni2023,
  author = {Giorgioni, Lorenzo and Ambrosone, Alessandra and Cometa, Maria Francesca and Salvati, Anna Laura and Magrelli, Armando},
  title = {CAR-T State of the Art and Future Challenges, A Regulatory Perspective},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241411803}
}
Kostenlos starten →